Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy

NCT05614453 is registered in ClinicalTrials.gov with Australia New Zealand Gynaecological Oncology Group as lead sponsor.

NCT NCT05614453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05614453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy
Lead sponsor
Australia New Zealand Gynaecological Oncology Group
Phase
Phase 2
Overall status
Withdrawn
Start date
June 30, 2023
Completion date
June 28, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic cervical cancer